Issue 3/2013
Content (20 Articles)
Pharmacological treatment of depression in women with breast cancer: a systematic review
Lærke Toftegård Andersen, Melissa Voigt Hansen, Jacob Rosenberg, Ismail Gögenur
Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis
April A. N. Rose, Christine Elser, Marguerite Ennis, Pamela J. Goodwin
DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA
Md Mizanur Rahman, Jyothi Maria Veigas, Paul J. Williams, Gabriel Fernandes
Analysis of phyllodes tumor recurrence according to the histologic grade
Sewha Kim, Ji-Ye Kim, Do Hee Kim, Woo Hee Jung, Ja Seung Koo
The expression of redox proteins in phyllodes tumor
Sewha Kim, Do Hee Kim, Woo Hee Jung, Ja Seung Koo
Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer
Kyle R. Covington, Lauren Brusco, Ines Barone, Anna Tsimelzon, Jennifer Selever, Arnoldo Corona-Rodriguez, Powel Brown, Rakesh Kumar, Susan G. Hilsenbeck, Suzanne A. W. Fuqua
Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents
Ingar Seemann, Johannes A. M. te Poele, Ji-Ying Song, Saske Hoving, Nicola S. Russell, Fiona A. Stewart
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Judy Dering, Jennifer Goldstein, Charles Ginther, Lee Anderson, Ming Lu, Teodora Kolarova, Mark A. Eckardt, Anita Langerød, Anne-Lise Børresen-Dale, Dennis J. Slamon, Richard S. Finn
The molecular diversity of Luminal A breast tumors
Giovanni Ciriello, Rileen Sinha, Katherine A. Hoadley, Anders S. Jacobsen, Boris Reva, Charles M. Perou, Chris Sander, Nikolaus Schultz
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
Kathryn J. Ruddy, Stephen D. Desantis, Rebecca S. Gelman, Alan H. B. Wu, Rinaa S. Punglia, Erica L. Mayer, Sara M. Tolaney, Eric P. Winer, Ann H. Partridge, Harold J. Burstein
Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma
Eleni Andreopoulou, Ivette S. Vigoda, Vicente Valero, Dawn L. Hershman, George Raptis, Linda T. Vahdat, Hyo S. Han, John J. Wright, Christine M. Pellegrino, Massimo Cristofanilli, Ricardo H. Alvarez, Karen Fehn, Susan Fineberg, Joseph A. Sparano
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Sara A. Hurvitz, Florence Dalenc, Mario Campone, Ruth M. O’Regan, Vivianne C. Tjan-Heijnen, Joseph Gligorov, Antonio Llombart, Haresh Jhangiani, Hamid R. Mirshahidi, Elizabeth Tan-Chiu, Sara Miao, Mona El-Hashimy, Jeremie Lincy, Tetiana Taran, Jean-Charles Soria, Tarek Sahmoud, Fabrice André
Genetic variants in microRNAs and breast cancer risk in African American and European American women
Song Yao, Kelly Graham, Jie Shen, Lara E. Sucheston Campbell, Prashant Singh, Gary Zirpoli, Michelle Roberts, Gregory Ciupak, Warren Davis, Helena Hwang, Thaer Khoury, Dana H. Bovbjerg, Lina Jandorf, Karen S. Pawlish, Elisa V. Bandera, Song Liu, Christine B. Ambrosone, Hua Zhao
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
Hope S. Rugo, Adam M. Brufsky, Marianne Ulcickas Yood, Debu Tripathy, Peter A. Kaufman, Musa Mayer, Bongin Yoo, Oyewale O. Abidoye, Denise A. Yardley
Clinical characteristics of breast cancer in patients with an NBS1 mutation
T. Huzarski, C. Cybulski, A. Jakubowska, T. Byrski, J. Gronwald, P. Domagała, M. Szwiec, D. Godlewski, E. Kilar, E. Marczyk, M. Siołek, B. Gorski, R. Wiśniowski, H. Janiszewska, D. Surdyka, R. Sibilski, P. Sun, S. A. Narod, J. Lubiński
Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers
Jun Sang Lee, Seho Park, Ji Min Park, Jung Hoon Cho, Seung Il Kim, Byeong-Woo Park
Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer
Ariadna Tibau, Marguerite Ennis, Pamela J. Goodwin
Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women’s health initiative
S. Wassertheil-Smoller, A. P. McGinn, N. Budrys, R. Chlebowski, G. Y. Ho, K. C. Johnson, D. S. Lane, W. Li, M. L. Neuhouser, J. Saquib, J. M. Shikany, Y. Song, C. Thomson
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
Dorien J. A. Lobbezoo, Roel J. W. van Kampen, Adri C. Voogd, M. Wouter Dercksen, Franchette van den Berkmortel, Tineke J. Smilde, Agnes J. van de Wouw, Frank P. J. Peters, Johanna M. G. H. van Riel, Natascha A. J. B. Peters, Maaike de Boer, George F. Borm, Vivianne C. G. Tjan-Heijnen
Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway
Chiara Guglielmi, Iacopo Cerri, Monica Evangelista, Anita Collavoli, Mariella Tancredi, Paolo Aretini, Maria Adelaide Caligo